Ambrx Inc., is a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code. Ambrx technology uses an expanded genetic code to incorporate synthetic amino acids into protein, all completed within a living cell. These synthetic amino acids enable the creation of Precision Biologics, an exciting new class of therapeutics with broad application and potential. This includes next-generation antibody drug conjugates (ADCs), bispecifics, and targeted immuno-oncology therapies for cancer as well as smart cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease.
Location: United States, California, San Diego
Employees: 51-200
Total raised: $297M
Founded date: 2003
Investors 5
| Date | Name | Website |
| - | M Ventures | m-ventures... |
| - | 5AM Ventur... | 5amventure... |
| 09.02.2022 | Matrix Par... | matrixpart... |
| - | HBM Partne... | hbmpartner... |
| - | Presidio P... | presidiopa... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 23.11.2020 | - | $200M | - |
| 05.08.2016 | - | $45M | - |
| 06.07.2006 | - | $52M | - |
Mentions in press and media 21
| Date | Title | Description | Source |
| 06.03.2024 | Ambrx Shareholders Approve Acquisition by Johnson & John... | - | globenewsw... |
| 09.01.2024 | Why Carta’s public battle might be a private markets nightma... | To say the Carta news that broke over the weekend has caused a furor in the startup world is an unde... | fortune.co... |
| 08.01.2024 | J&J Joins the Cancer ADC Dealmaking Spree With $2B Ambrx... | Big pharmaceutical companies splashed out big bucks in 2023 to acquire or license antibody drug conj... | medcitynew... |
| 20.06.2023 | This Startup Is Rewriting The Language Of Life To Make Smart... | Pearl Bio co-founders: Michael Jewett, Amy Cayne Schwartz, and Farren Isaacs.Pearl Bio. | forbes.com... |
| 19.10.2022 | Biotech layoffs continue as Ambrx cuts staff and part of... | It’s been no secret that this year has been rough for biotechs and employees, as companies have... | endpts.com... |
| 21.06.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM por... | Ambrx Biopharma (NYSE: AMAM), a private company in the portfolio of HBM Healthcare Investments, comp... | hbmhealthc... |
| 07.01.2021 | Ambrx Appoints Gary Yeung as Chief Financial Officer and Chi... | prnewswire... | |
| 24.11.2020 | After 5 quiet years, a former Scripps spinout raises $2... | The first time San Diego biotech Ambrx tried to go public in 2014, they failed and the company’s... | endpts.com... |
| 23.11.2020 | $200M investment to advance clinical programs for Ambrx | Investors in the $200 million round include Fidelity Management & Research Co., Cormorant Asset ... | medcitynew... |
| 23.11.2020 | Ambrx has raised a massive $200M round to advance work on it... | - | connect.or... |
Show more